Orphan drug Designation for Anti-Pseudomonas IgY
Swedish biotech company IMMUNSYSTEM I.M.S. AB announces that the European Medicines Agency, EMEA, has granted an orphan drug designation to the drug candidate Anti-Pseudomonas IgY for use in the treatment of cystic fibrosis. "This is the first pharmaceutical preparation in the world derived from avian antibodies for the treatment of patients with Cystic Fibrosis" says Per Omstedt, CEO.
Read the press release
(Svenska)
Read the
press release (English)
Anti-Pseudomonas IgY
Immunotherapy with IgY is by design a low toxicity treatment and is therefore ideally suited for long term prophylaxis, even more so for conditions where it is simply not possible to stay away from the microorganisms that cause the infection.
Cystic Fibrosis
Cystic fibrosis is one of the most common life-shortening, childhood-onset inherited diseases and in caucasian populations, it is the most common life-shortening genetic disease.
